– Bradford Cross, Chief Technology Officer to transition; Don Gehlert, PhD, Chief Scientific Officer to transition to Senior Scientific Advisor – NEW YORK, Dec. 29, 2021 /CNW/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-inspired therapies, today announced that its Chief Technology Officer, Bradford Cross…


Previous articleCOMPASS Patent Challenge Targets Crystallography Errors
Next articleTryp Therapeutics Announces Advancement of Phase 2a Clinical Trial in Binge Eating Disorder